Previous Close | 0.0450 |
Open | 0.0500 |
Bid | 0.0450 x N/A |
Ask | 0.0500 x N/A |
Day's Range | 0.0450 - 0.0500 |
52 Week Range | 0.0350 - 0.2500 |
Volume | |
Avg. Volume | 63,677 |
Market Cap | 9.504M |
Beta (5Y Monthly) | 1.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0300 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors due to the requirements of a new role, effective April 30, 2024.
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, will be participating in the Water Tower Research Fireside Chat Series on April 4, 2024, at 12:00 pm ET.
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2023.